Stockholm's Eyedentity raises €1.3 million to spot deadly eye cancer earlier using AI
Swedish startup Eyedentity has secured €1.3 million to advance an AI tool for early detection of uveal melanoma, a rare but dangerous eye cancer. The funding will support regulatory approval and expansion into opticians, eye clinics and hospitals.
Stockholm-based MedTech startup Eyedentity has closed its first investment round, which was oversubscribed, raising €1.3 million (SEK 15 million). The round was led by Norrsken Launcher, with participation from Karolinska Institutet Innovation and a group of angel investors.
Founded in 2025, Eyedentity is building AI technology that analyses fundus images already captured during routine eye examinations to detect serious eye diseases. Its first focus is uveal melanoma, a rare but potentially fatal form of eye cancer that can be hard to distinguish from benign conditions, especially in its early stages.
The company was founded by Gustav Stålhammar, an ocular oncologist at St. Erik Eye Hospital and professor at Karolinska Institutet, together with Mats Holmström, a machine learning engineer previously involved in applying AI to cancer care.
The platform is designed to fit into opticians' existing workflow: during a routine exam, an optician can upload existing fundus images for analysis, and the system provides decision support on whether a patient should be referred to a specialist. No new imaging equipment or separate screening process is required. According to the company, the system can cut false-positive referrals by 90%, helping specialist services focus on patients who genuinely need further investigation.
Eyedentity is currently running a live pilot with Synologen, a network of independent opticians in Sweden, with plans to move toward commercialisation in the Nordics before expanding into wider Europe and the US. The new funding will go toward pursuing full regulatory approval for the first product, developing additional diagnostic features, and growing the team.
The startup is part of the Karolinska Institutet Innovation Incubator. Beyond uveal melanoma, it plans to extend its platform to other eye conditions, including diabetic retinopathy and glaucoma, aiming to become a broader AI diagnostics platform for opticians, eye clinics and hospitals.
